Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes

The major trials, e.g., EMPA-REG OUTCOME, CANVAS, and CREDENCE, showed the renal and cardiovascular benefit of sodium-glucose transport protein 2 (SGLT2) inhibitors. The SGLT2 inhibitors, Empagliflozin, Dapagliflozin, and Canagliflozin, have shown no significant adverse renal effects. Still, our pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Rajesh, Bhavatharini, Natrajan, Saravanan, Thangavel, Seshiah, Veeraswamy, Jain, Nishchal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840745/
https://www.ncbi.nlm.nih.gov/pubmed/36654590
http://dx.doi.org/10.7759/cureus.32573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840745/
https://www.ncbi.nlm.nih.gov/pubmed/36654590
http://dx.doi.org/10.7759/cureus.32573

Ejemplares similares